前列地尔注射液治疗缺血性卒中疗效及安全性的Meta分析  

Meta-analysis of Therapeutic Efficacy and Safety of Alprostadil Injection in the Treatment of Ischemic Stroke

作　　者：霍墨菲[1] 李文杰[2] 孙瑞华[2] 

机构地区：[1]北京中医药大学管理学院,北京100029 [2]中日友好医院科研处,北京100029

出　　处：《中国药房》2012年第32期3035-3037,共3页China Pharmacy

摘　　要：目的:系统评价前列地尔注射液治疗缺血性卒中的疗效与安全性。方法:计算机检索万方数据库、维普数据库和中国期刊全文数据库(CNKI),收集前列地尔注射液治疗缺血性卒中的随机对照试验(RCT),评价纳入研究的方法学质量,并提取数据使用Rev man 5.0软件进行Meta分析。结果:共纳入8项RCT,合计618例患者。Meta分析结果显示,前列地尔注射液在改善临床疗效和神经功能缺损评分方面均优于对照组,2组总有效率比较差异有统计学意义[OR=4.54,95%CI(2.46,8.41),P<0.00001];2组改善神经功能缺损评分比较差异有统计学意义[WMD=-2.60,95%C(I-3.99,-1.20),P=0.0003];2组不良反应发生率比较差异亦有统计学意义(P<0.0001)。结论:前列地尔注射液用于缺血性卒中疗效好且较为安全。OBJECTIVE： To evaluate the clinical efficacy and the safety of Alprostadil injection for ischemic stroke. METH- ODS： Retrieved from Wanfang, VIP, CNKI database, RCTs on Alprostadil injection as intervention measures for ischemic stroke were collected. The methodological quality of the trials was evaluated. A Meta-analysis of included clinical trials was performed with Rev man 5.0 software. RESULTS： 8 trials were included with a total of 618 petients. Results of Meta-analysis showed that the improvement of clinical efficacy [OR= 4.54, 95 % CI （2.46,8.41 ）, P〈 0.000 01] and neurological deficit score [WMD = - 2.60, 95%CI（-3.99,- 1.20）, P=0.000 3] in Alprostadil injection group were superior to control group. There was statistical difference. There was statistical difference in the incidence of ADR between 2 groups （P〈0.000 1）. CONCLUSION： Alprostadil injection showed advantage in the improvement of clinical efficacy and neurological deficit score with less ADR rate.

关 键 词：缺血性卒中 前列地尔注射液 随机对照试验 META分析 

分 类 号：R971[医药卫生—药品] R969.4[医药卫生—药学]